A systems biology approach to defining metastatic biomarkers and signaling pathways

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 1, Issue 1, 2009, Pages 89-96

  Goldberger, Natalie E ^a   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

COMPARATIVE GENOMIC HYBRIDIZATION; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PROTEOMICS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952113836     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.6     Document Type: Article

References (83)

1. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12(8):895-904.
2. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
3. Ramaswamy S, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33(1):49-54.
4. Bernards R, Weinberg RA. A progression puzzle. Nature 2002, 418(6900):823.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
6. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007, 8(5):341-352.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70.
8. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
9. Weigelt B, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003, 100(26):15901-15905.
10. Lifsted T, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998, 77(4):640-644.
11. Hunter KW, et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 2001, 61(24):8866-8872.
12. Park YG, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005, 37(10):1055-1062.
13. Crawford NP, et al. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006, 8(2):R16.
14. Hemminki K, et al. Survival in breast cancer is familial. Breast Cancer Res Treat 2008, 110(1):177-182.
15. Hemminki K, et al. Concordance of survival in family members with prostate cancer. J Clin Oncol 2008, 26(10):1705-1709.
16. Lindstrom LS, et al. Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol 2007, 8(11):1001-1006.
17. Ji J, et al. Survival in bladder and renal cell cancers is familial. J Am Soc Nephrol 2008, 19(5):985-991.
18. Minn AJ, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
19. Kang Y, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
20. Chang HY, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743.
21. Chi JT, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3(3):e47.
22. West RB, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005, 3(6):e187.
23. Buess M, et al. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol 2007, 8(9):R191.
24. Lu J, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
25. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
26. Calin GA, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004, 101(32):11755-11760.
27. Iorio MV, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070.
28. Yu SL, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13(1):48-57.
29. Yanaihara N, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(3):189-198.
30. Michael MZ, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1(12):882-891.
31. Liu CG, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004, 101(26):9740-9744.
32. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res 2008, 10(2):203.
33. Korpal M, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283(22):14910-14914.
34. Tavazoie SF, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451(7175):147-152.
35. Zhu S, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008, 18(3):350-359.
36. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163):682-688.
37. Huang Q, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008, 10(2):202-210.
38. Zhang L, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006, 103(24):9136-9141.
39. Calin GA, et al. Frequent deletions and downregulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99(24):15524-15529.
40. Pollack JR, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002, 99(20):12963-12968.
41. Kim M, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006, 125(7):1269-1281.
42. Mhawech-Fauceglia P, et al. Array-based Comparative Genomic Hybridization (aCGH) analysis is a useful tool for distinguishing primary pulmonary from metastatic neuroendocrine carcinoma to the lung. Appl Immunohistochem Mol Morphol 2008, 16(3):291-295.
43. Chin SF, et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007, 26(13):1959-1970.
44. Chin K, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541.
45. Chin SF, et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007, 8(10):R215.
46. Paris PL, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004, 13(13):1303-1313.
47. Takahashi K, et al. Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res 2007, 13(1):111-120.
48. Namba R, et al. Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 2006, 6:275.
49. Fuhrmann C, et al. High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res 2008, 36(7):e39.
50. Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003, 4(1):4-6.
51. Pelham RJ, et al. Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci USA 2006, 103(52):19848-19853.
52. Qiu W, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008, 40(5):650-655.
53. Allinen M, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6(1):17-32.
54. Tuhkanen H, et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer 2004, 109(2):247-252.
55. Weber F, et al. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet 2006, 78(6):961-972.
56. Gygi SP, et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19(3):1720-1730.
57. Hathout Y, et al. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett 2004, 210(2):245-253.
58. Rivera J, Megias D, Bravo J. Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. J Proteome Res 2007, 6(10):4006-4018.
59. Lee JH, et al. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Cancer Res 2008, 68(3):639-644.
60. Chen YR, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 2006, 5(10):2727-2742.
61. Yang H, et al. Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications. J Proteome Res 2006, 5(7):1555-1567.
62. Kononen J, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847.
63. Kallioniemi OP, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10(7):657-662.
64. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8(11):1323-1327.
65. Berger AJ, et al. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 2004, 64(23):8767-8772.
66. Rubin MA, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004, 164(3):831-840.
67. Kluger HM, et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005, 65(13):5578-5587.
68. Varambally S, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(5):393-406.
69. Hwang SI, et al. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 2007, 26(1):65-76.
70. Danna EA, Nolan GP. Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. Curr Opin Chem Biol 2006, 10(1):20-27.
71. Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci USA 1999, 96(26):14694-14699.
72. DeClerck YA, et al. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997, 425:89-97.
73. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer.Eur J Cancer 1994, 30A(14):2170-2180.
74. Jessani N, et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 2004, 101(38):13756-13761.
75. Crawford NP, Hunter KW. New perspectives on hereditary influences in metastatic progression. Trends Genet 2006, 22(10):555-561.
76. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.
77. Frank SA. Genetic predisposition to cancer-insights from population genetics. Nat Rev Genet 2004, 5(10):764-772.
78. Hunter KW. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett 2003, 200(2):97-105.
79. Hunter KW. Host genetics and tumour metastasis. Br J Cancer 2004, 90(4):752-755.
80. Hunter K, Welch DR, Liu ET. Genetic background is an important determinant of metastatic potential. Nat Genet 2003, 34(1):23-24.
81. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006, 6(2):146-155.
82. Kang Y. Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. Expert Rev Mol Diagn 2005, 5(3):385-395.
83. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24(8):971-983